Seres Therapeutics (NASDAQ:MCRB) reported quarterly earnings of $0.47 per share which beat the analy

Recently announced 80% of SER-155 recipients achieved immunosuppressive-free clinical response at da

Seres Therapeutics NASDAQ: MCRB reported results from an investigator-sponsored study of SER-155 in

Seres Therapeutics Inc. (NASDAQ:MCRB) on Wednesday reported topline results from an investigator-spo

Seres Therapeutics reported early SER-155 data, with 80% of patients achieving steroid-free clinical

Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkp

The study (NCT06801067), conducted at MSK, by Principal Investigator David Faleck, M.D., Director of

80% of SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary s

 The IST was conducted at Memorial Sloan Kettering Cancer Center, with which Seres has a long histor

CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leadi

Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page fo

HC Wainwright & Co. analyst Matthew Keller initiates coverage on Seres Therapeutics (NASDAQ:M

Seres Therapeutics, Inc. (NASDAQ:MCRB), ("Seres" or the "Company"), a leading live b

Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of p

CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leadin

Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(2.08) per share which missed the ana

Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related en

Seres Therapeutics, Inc. (NASDAQ:MCRB) (Seres or the Company), a leading live biotherapeutics compan

Data highlight both SER-603's rational design that targets microbial functions linked to mucosal

Data highlight both SER-603's rational design that targets microbial functions linked to mucosal hea

Presentations DetailsPoster Presentation (Abstract 1726)Title: Effect of investigational, live bioth

Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrie

Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrie

CAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres

Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(1.76) per share which beat the analy

Readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a freque

Seres Therapeutics, Inc. (MCRB) Discusses Leadership Transition, Strategic Direction and Microbiome

Seres Therapeutics, Inc. (NASDAQ:MCRB), (Seres or the Company), a leading live biotherapeutics compa

Accomplished pharmaceutical executive brings extensive business development, licensing and finance e

Seres Therapeutics Inc. (NASDAQ: MCRB) shares are down during Thursday's premarket session following

Seres stock drops after pausing a key drug study and cutting 30% of staff. The company shifts focus

Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic

Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic

Shares of Seres Therapeutics, Inc. (NASDAQ: MCRB - Get Free Report) crossed below its 50-day moving

Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recur